​

ANI Pharmaceuticals (ANIP) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

ANIP Stock Forecast

ANI Pharmaceuticals (ANIP) stock forecast, based on 10 Wall Street analysts, predicts a 12-month average price target of $104.75, with a high of $121.00 and a low of $90.00. This represents a 12.80% increase from the last price of $92.86.

$55 $69 $83 $97 $111 $125 High: $121 Avg: $104.75 Low: $90 Last Closed Price: $92.86

ANIP Stock Rating

ANI Pharmaceuticals stock's rating consensus is Buy, based on 10 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 7 Buy (70.00%), 3 Hold (30.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 10 0 3 7 Strong Sell Sell Hold Buy Strong Buy

ANIP Price Target Upside V Benchmarks

TypeNameUpside
StockANI Pharmaceuticals12.80%
SectorHealthcare Stocks 15.45%
IndustrySpecialty & Generic Drug Manufacturers Stocks18.71%

Price Target Trends

1M3M12M
# Anlaysts145
Avg Price Target$90.00$104.75$101.00
Last Closing Price$92.86$92.86$92.86
Upside/Downside-3.08%12.80%8.77%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Oct, 25431--8
Sep, 25431--8
Aug, 25331--7
Jul, 25231--6
Jun, 25231--6
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Oct 09, 2025Truist Financial$90.00$91.63-1.78%-3.08%
Sep 17, 2025Brandon FolkesH.C. Wainwright$121.00$95.3626.89%30.30%
Sep 08, 2025Vamil DivanGuggenheim$114.00$95.2019.75%22.77%
Aug 08, 2025David AmsellemPiper Sandler$94.00$81.1315.86%1.23%
Mar 05, 2025Guggenheim$86.00$59.6844.10%-7.39%
Sep 18, 2024Gary NachmanRaymond James$83.00$61.2335.55%-10.62%
Sep 11, 2024Les SulewskiTruist Financial$60.00$55.488.15%-35.39%
Jun 26, 2024Oren LivnatH.C. Wainwright$94.00$65.4943.53%1.23%
May 13, 2024Oren LivnatH.C. Wainwright$87.00$68.0627.83%-6.31%
Aug 09, 2022Raymond James$48.00$34.8737.65%-48.31%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Sep 17, 2025H.C. WainwrightBuyBuyhold
Sep 08, 2025GuggenheimBuyBuyhold
Aug 08, 2025H.C. WainwrightBuyBuyhold
Aug 08, 2025Piper SandlerOverweightOverweighthold
Jul 10, 2025H.C. WainwrightBuyBuyinitialise
Mar 05, 2025GuggenheimBuyBuyhold
Oct 22, 2024Truist FinancialBuyBuyhold
Oct 11, 2024Raymond JamesBuyBuyhold
Oct 11, 2024Piper SandlerOverweightinitialise
Sep 18, 2024Raymond JamesOutperformOutperformhold

Financial Forecast

EPS Forecast

$-5 $-2 $1 $4 $7 $10 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-1.88$-3.38$-2.95$0.95$-0.87----
Avg Forecast$3.65$3.46$1.37$4.52$5.01$5.56$6.60$7.33$8.08
High Forecast$3.81$3.61$1.39$4.56$5.09$6.21$7.97$7.85$8.28
Low Forecast$3.28$3.11$1.33$4.45$4.90$4.76$4.41$6.82$7.84
Surprise %-151.51%-197.69%-315.33%-78.98%-117.37%----

Revenue Forecast

$150M $300M $450M $600M $750M $900M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$208.47M$216.14M$316.38M$486.82M$614.38M----
Avg Forecast$205.37M$211.60M$306.90M$479.84M$599.21M$724.93M$773.93M$811.16M$846.28M
High Forecast$212.42M$218.87M$311.29M$487.08M$600.51M$738.71M$788.59M$826.53M$862.31M
Low Forecast$189.53M$195.28M$300.34M$476.13M$597.60M$703.61M$756.73M$793.14M$827.47M
Surprise %1.51%2.14%3.09%1.45%2.53%----

Net Income Forecast

$-150M $-80M $-10M $60M $130M $200M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-22.55M$-42.60M$-47.90M$18.78M$-18.52M----
Avg Forecast$66.35M$62.95M$-88.64M$15.47M$90.82M$99.76M$112.60M$133.41M$146.96M
High Forecast$69.31M$65.76M$-70.91M$18.57M$92.55M$112.99M$144.99M$142.76M$150.58M
Low Forecast$59.69M$56.64M$-106.37M$12.38M$89.09M$86.52M$80.22M$124.05M$142.72M
Surprise %-133.98%-167.68%-45.96%21.35%-120.39%----

ANIP Forecast FAQ

Is ANI Pharmaceuticals stock a buy?

ANI Pharmaceuticals stock has a consensus rating of Buy, based on 10 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 7 Buy, 3 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that ANI Pharmaceuticals is a favorable investment for most analysts.

What is ANI Pharmaceuticals's price target?

ANI Pharmaceuticals's price target, set by 10 Wall Street analysts, averages $104.75 over the next 12 months. The price target range spans from $90 at the low end to $121 at the high end, suggesting a potential 12.80% change from the previous closing price of $92.86.

How does ANI Pharmaceuticals stock forecast compare to its benchmarks?

ANI Pharmaceuticals's stock forecast shows a 12.80% upside, underperforming the average forecast for the healthcare stocks sector (15.45%) and underperforming the specialty & generic drug manufacturers stocks industry (18.71%).

What is the breakdown of analyst ratings for ANI Pharmaceuticals over the past three months?

  • October 2025: 50.00% Strong Buy, 37.50% Buy, 12.50% Hold, 0% Sell, 0% Strong Sell.
  • September 2025: 50.00% Strong Buy, 37.50% Buy, 12.50% Hold, 0% Sell, 0% Strong Sell.
  • August 2025: 42.86% Strong Buy, 42.86% Buy, 14.29% Hold, 0% Sell, 0% Strong Sell.

What is ANI Pharmaceuticals’s EPS forecast?

ANI Pharmaceuticals's average annual EPS forecast for its fiscal year ending in December 2025 is $5.56, marking a -739.08% decrease from the reported $-0.87 in 2024. Estimates for the following years are $6.6 in 2026, $7.33 in 2027, and $8.08 in 2028.

What is ANI Pharmaceuticals’s revenue forecast?

ANI Pharmaceuticals's average annual revenue forecast for its fiscal year ending in December 2025 is $724.93M, reflecting a 17.99% increase from the reported $614.38M in 2024. The forecast for 2026 is $773.93M, followed by $811.16M for 2027, and $846.28M for 2028.

What is ANI Pharmaceuticals’s net income forecast?

ANI Pharmaceuticals's net income forecast for the fiscal year ending in December 2025 stands at $99.76M, representing a -638.60% decrease from the reported $-18.522M in 2024. Projections indicate $112.6M in 2026, $133.41M in 2027, and $146.96M in 2028.